Pleno is an early-stage San Diego clinical and multi-omics diagnostics company developing the RAPTOR™ multi-omic instrument platform to revolutionize biological target detection. Its Hypercoding™ technology is designed to simplify known-target detection and deliver improvements in performance, cost, and scale. The company says the platform enables a broad array of life-science and clinical applications, including oncology and infectious disease. Pleno is preparing to scale its commercial operations and begin commercialization as it moves into its next phase of growth. The company recently closed a $25 million Series B and appointed Dr. Vik Vaz, M.D. as CEO to lead commercial expansion and execution. Pleno develops a multi-omic instrument platform built on proprietary Hypercoding™ technology that leverages telecom-derived signal processing to deliver ultra-high plex targeted biological information including DNA, RNA, methylation, and proteomic content. Its flagship instrument platform, RAPTOR™, is designed to provide ultra-high target multiplexing, high dynamic range, very low limit of detection, and throughput of 8–384 samples per run with 1–3 hour runtimes depending on assay needs. The company plans early customer access to RAPTOR in 2023 and full availability in 2024, and says newly raised funds will accelerate platform development. Pleno is based in San Diego’s Sorrento Mesa innovation hub and currently employs 24 full-time employees, with plans to grow the team. Cited target applications include early cancer screening, NIPT, infectious diseases, pharmacogenomics, proteomics, and agrigenomics. The platform is positioned to reduce cost and broaden access to high-plex diagnostics for clinical and research use. Pleno has developed Hypercoding™, a signal‑processing–based platform that delivers ultra‑high plex targeted biological information across DNA, RNA, methylation, and proteomic content. Its instrument platform is designed to detect up to 10,000 targets per sample and process up to 10,000 samples per day via a simple, low‑cost workflow. The company says this represents ~1,000× PCR multiplexing and ~100× NGS sample throughput. Pleno plans to use the newly raised funds to advance development of the Hypercoding™ instrument and scale operations. Management highlights potential clinical applications such as liquid biopsies and aims to democratize clinical multi‑omics. The company is led by Founder and CEO Pieter van Rooyen and recently added Gregory T. Lucier as Chairman of the Board. Pleno is based in San Diego’s Sorrento Mesa and currently employs 14 full‑time employees.

Total raised

$80M

Funding rounds

3

Latest round

Series B

Latest activity

Dec 2024